ImmunoCellular Therapeutics is a clinical-stage company developing immune-based therapies designed to improve the diagnosis and the treatment of brain and other cancers with high unmet medical needs. ImmunoCellular’s lead product candidate ICT-107 is in a phase II trial as a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. For more information visit the company’s Web site at www.imuc.com

ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com

Let us hear your thoughts below: